Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Regeneron Pharmaceuticals Inc REGN
News
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
REGN 4-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
United States